ImmuLogic cocaine vaccine therapy R&D to be funded by NIDA grant; clinicals forecast for early to mid-1997.
Executive Summary
IMMULOGIC COCAINE VACCINE R&D WILL BE SUPPORTED BY NIDA through a Small Business Innovation Research grant, Waltham, Mass.-based ImmuLogic announced Aug. 2. The $700,000 SBIR grant "will make it possible to expeditiously optimize the design of the cocaine vaccine and its administration to humans while assessing the vaccine's efficacy in further animal models." ImmuLogic also may employ the same technology to treat nicotine addiction, the firm said.